vs
Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and ENANTA PHARMACEUTICALS INC (ENTA). Click either name above to swap in a different company.
ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $13.8M, roughly 1.3× CB Financial Services, Inc.). On growth, CB Financial Services, Inc. posted the faster year-over-year revenue change (19.9% vs 9.8%). CB Financial Services, Inc. produced more free cash flow last quarter ($17.2M vs $-11.8M). Over the past eight quarters, ENANTA PHARMACEUTICALS INC's revenue compounded faster (4.5% CAGR vs 1.2%).
CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
CBFV vs ENTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $18.6M |
| Net Profit | — | $-11.9M |
| Gross Margin | — | — |
| Operating Margin | 38.1% | -60.5% |
| Net Margin | — | -64.1% |
| Revenue YoY | 19.9% | 9.8% |
| Net Profit YoY | — | 46.4% |
| EPS (diluted) | $0.90 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $18.6M | ||
| Q3 25 | $2.4M | $15.1M | ||
| Q2 25 | $13.5M | $18.3M | ||
| Q1 25 | $12.1M | $14.9M | ||
| Q4 24 | $13.2M | $17.0M | ||
| Q3 24 | $12.7M | $14.6M | ||
| Q2 24 | $12.2M | $18.0M | ||
| Q1 24 | $13.5M | $17.1M |
| Q4 25 | — | $-11.9M | ||
| Q3 25 | $-5.7M | $-18.7M | ||
| Q2 25 | $3.9M | $-18.3M | ||
| Q1 25 | $1.9M | $-22.6M | ||
| Q4 24 | — | $-22.3M | ||
| Q3 24 | $3.2M | $-28.8M | ||
| Q2 24 | $2.6M | $-22.7M | ||
| Q1 24 | $4.2M | $-31.2M |
| Q4 25 | 38.1% | -60.5% | ||
| Q3 25 | -289.8% | -121.6% | ||
| Q2 25 | 35.0% | -103.2% | ||
| Q1 25 | 19.3% | -164.3% | ||
| Q4 24 | 23.1% | -138.8% | ||
| Q3 24 | 31.2% | -204.4% | ||
| Q2 24 | 26.4% | -134.6% | ||
| Q1 24 | 37.9% | -192.1% |
| Q4 25 | — | -64.1% | ||
| Q3 25 | -235.2% | -123.6% | ||
| Q2 25 | 29.3% | -99.7% | ||
| Q1 25 | 15.8% | -151.7% | ||
| Q4 24 | — | -131.4% | ||
| Q3 24 | 25.3% | -197.3% | ||
| Q2 24 | 21.8% | -126.1% | ||
| Q1 24 | 31.1% | -182.7% |
| Q4 25 | $0.90 | $-0.42 | ||
| Q3 25 | $-1.07 | $-0.88 | ||
| Q2 25 | $0.74 | $-0.85 | ||
| Q1 25 | $0.35 | $-1.06 | ||
| Q4 24 | $0.45 | $-1.05 | ||
| Q3 24 | $0.60 | $-1.36 | ||
| Q2 24 | $0.51 | $-1.07 | ||
| Q1 24 | $0.82 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $37.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $157.5M | $126.6M |
| Total Assets | $1.5B | $329.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $37.4M | ||
| Q3 25 | $55.9M | $32.3M | ||
| Q2 25 | $64.5M | $44.8M | ||
| Q1 25 | $61.3M | $60.2M | ||
| Q4 24 | $49.6M | $84.3M | ||
| Q3 24 | $147.3M | $37.2M | ||
| Q2 24 | $142.6M | $35.8M | ||
| Q1 24 | $73.7M | $63.5M |
| Q4 25 | $157.5M | $126.6M | ||
| Q3 25 | $152.5M | $64.7M | ||
| Q2 25 | $148.4M | $79.3M | ||
| Q1 25 | $148.3M | $93.5M | ||
| Q4 24 | $147.4M | $111.8M | ||
| Q3 24 | $149.1M | $128.8M | ||
| Q2 24 | $142.9M | $148.9M | ||
| Q1 24 | $141.6M | $166.1M |
| Q4 25 | $1.5B | $329.5M | ||
| Q3 25 | $1.5B | $280.7M | ||
| Q2 25 | $1.5B | $301.0M | ||
| Q1 25 | $1.5B | $323.0M | ||
| Q4 24 | $1.5B | $348.6M | ||
| Q3 24 | $1.6B | $376.7M | ||
| Q2 24 | $1.6B | $398.8M | ||
| Q1 24 | $1.5B | $413.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | $-11.7M |
| Free Cash FlowOCF − Capex | $17.2M | $-11.8M |
| FCF MarginFCF / Revenue | 124.1% | -63.6% |
| Capex IntensityCapex / Revenue | 4.7% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.5M | $-18.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.8M | $-11.7M | ||
| Q3 25 | $4.6M | $-6.5M | ||
| Q2 25 | $4.1M | $17.5M | ||
| Q1 25 | $4.0M | $-13.5M | ||
| Q4 24 | $6.8M | $-16.8M | ||
| Q3 24 | $3.1M | $-10.4M | ||
| Q2 24 | $-1.2M | $-14.8M | ||
| Q1 24 | $3.3M | $-28.6M |
| Q4 25 | $17.2M | $-11.8M | ||
| Q3 25 | $4.5M | $-7.9M | ||
| Q2 25 | $3.9M | $17.4M | ||
| Q1 25 | $3.9M | $-16.0M | ||
| Q4 24 | $3.4M | $-25.5M | ||
| Q3 24 | $2.2M | $-19.4M | ||
| Q2 24 | $-2.4M | $-21.3M | ||
| Q1 24 | $2.3M | $-30.3M |
| Q4 25 | 124.1% | -63.6% | ||
| Q3 25 | 186.5% | -52.5% | ||
| Q2 25 | 28.8% | 94.7% | ||
| Q1 25 | 32.5% | -107.4% | ||
| Q4 24 | 26.0% | -150.6% | ||
| Q3 24 | 17.4% | -132.5% | ||
| Q2 24 | -19.6% | -118.6% | ||
| Q1 24 | 17.0% | -177.5% |
| Q4 25 | 4.7% | 0.8% | ||
| Q3 25 | 4.3% | 9.6% | ||
| Q2 25 | 1.9% | 0.8% | ||
| Q1 25 | 0.8% | 17.0% | ||
| Q4 24 | 25.1% | 51.6% | ||
| Q3 24 | 6.7% | 61.3% | ||
| Q2 24 | 10.0% | 36.4% | ||
| Q1 24 | 7.2% | 9.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
